Clinical trials: Blood Platelets, open to volunteers
Immune Thrombocytopenia
Safety and Efficacy of PRG-1801 in Recurrent/Refractory Primary Immune Thrombocytopenia (ITP)
This is a single center, open-label, 3+3 dose escalation, early phase 1 study to evaluate the safety, tolerability, and preliminary efficacy of PRG-1801 for patients with relapsed/refractory immune thrombocytopenia (ITP).
- Trial name
- NCT06519565
- Testing
- PRG-1801
- Where
- 2 sites in China
- Volunteers
- 6 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Thrombosis, Blood Coagulation Disorder
Dynamics of Platelet Activation in Patients With Ventricular Assist Device (VAD)
Consenting patients with end-stage heart failure that are implanted with/candidates for implant of a short-term/durable mechanical circulatory support device (e.g.: percutaneous microaxial pumps (Impella), extracorporeal membrane…
- Conditions
- Thrombosis, Blood Coagulation Disorder, Platelet Thrombus, Platelet Dysfunction Due to Aspirin
- Trial name
- PASVAD (NCT03255928)
- Testing
- PAS assay, TGT
- Where
- Italy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Scientific Institute San Raffaele
Primary Immune Thrombocytopenia (ITP)
A PHASE II TRIAL AIMING TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA PREVIOUSLY TREATED WITH A THROMBOPOIETIN RECEPTOR AGONIST AND/OR RITUXIMAB AFTER CORTICOSTEROID FIRST-LINE THERAPY
This is a Phase II open label, prospective, multicenter trial designed to assess the safety and clinical activity of belantamab mafodotin in adult patients with primary immune thrombocytopenia (ITP) previously treated with a…
- Trial name
- BONSAI (NCT07019545)
- Testing
- Belantamab Mafodotin, Dexamethasone
- Where
- Greece
- Volunteers
- 14 people
- Sponsor
- Hellenic Society of Hematology
Glanzmann Thrombasthenia
Eptacog Beta in Glanzmann's (HeT_LFB-Strength-Study_FID531)
This study is evaluating an investigational drug, eptacog beta (EB), for the treatment and prevention of acute bleeding episodes in people with Glanzmann Thrombasthenia, a rare inherited bleeding disorder.
- Trial name
- STRENGTH (NCT07136857)
- Testing
- EPTACOG BETA
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Emory University
Immune Thrombocytopenia
Safety and Efficacy of GL-2045 in Patients With Immune Thrombocytopenia
The goal of this clinical trial is to demonstrate GL-2045 safety and efficacy proof of concept by demonstrating intravenous immunoglobulin (IVig)-like platelet responses in adult patients with Immune Thrombocytopenia (ITP).
- Trial name
- NCT07605845
- Testing
- GL-2045
- Where
- United Kingdom
- Volunteers
- 42 people
- Sponsor
- Gliknik Inc.
Neonatal Sepsis, Sepsis
CBC Indices and Serum Lactate in Neonatal Sepsis
Neonatal sepsis is a leading cause of illness and death in Neonatal Intensive Care Units (NICUs). Diagnosing it quickly is challenging because the early signs often overlap with other common newborn health issues.
- Trial name
- NCT07663084
- Volunteers
- 80 people
- Sponsor
- Assiut University
Immune Thrombocytopenia, Autoimmune Hemolytic Anemia
French Registry of Adult Patients With Immune Thrombocytopenia and Autoimmune Hemolytic Anemia
CARMEN is a national, real-world clinical registry of all adult patients with incident diagnosis of Immune thrombocytopenia (ITP) or Autoimmune Hemolytic anemia (AIHA) patients in France.
- Trial name
- CARMEN (NCT02877706)
- Testing
- no specific intervention
- Where
- France
- Volunteers
- 1,500 people
- Sponsor
- University Hospital, Toulouse
Immune Thrombocytopenia, Treatment
Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
This single-arm, open-label phase II study aim to evaluate the efficacy and safety of Daratumumab (anti-CD38 monoclonal antibody) combined with Rituximab in ITP patients.This study will be conducted in ITP patients who had not…
- Trial name
- NCT07362199
- Testing
- Rituximab combined with Daratumumab（Anti-CD38 Monoclonal Antibody）
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
AIHA - Warm Autoimmune Hemolytic Anemia, AIHA - Cold Autoimmune Hemolytic Anemia
OM336 in Autoimmune Cytopenias
An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of subcutaneously dosed OM336 in adult participants with autoimmune cytopenias.
- Conditions
- AIHA - Warm Autoimmune Hemolytic Anemia, AIHA - Cold Autoimmune Hemolytic Anemia, ITP - Immune Thrombocytopenia
- Trial name
- NCT07083960
- Testing
- OM336
- Where
- 7 sites in United States, Australia
- Volunteers
- 32 people
- Sponsor
- Lakefront Biotherapeutics West LLC
Immune Thrombocytopenia, Treatment
A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia
To evaluate the safety and efficacy of nicotinamide adenine dinucleotide in the treatment of immune thrombocytopenia in patients who have not responded adequately or relapsed after first-line treatment and at least one…
- Trial name
- NCT06776510
- Testing
- nicotinamide adenine dinucleotid/nicotinamide mononucleotide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Two Step Haplo With Radiation Conditioning
This phase II clinical trial evaluates whether a modified modality of conditioning reduces treatment-related mortality (TRM) in patients who undergo a hematopoietic stem cell transplant (HSCT) for a hematological malignancy.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Adult T-Cell Leukemia/Lymphoma, Aplastic Anemia
- Trial name
- NCT05031897
- Testing
- Fludarabine, Total-Body Irradiation, Donor Lymphocyte Infusion
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Thomas Jefferson University
Clonal Cytopenia of Undetermined Significance, Essential Thrombocythemia
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
This phase II trial evaluates how a curcumin supplement (C3 complex/Bioperine) changes the inflammatory response and symptomatology in patients with clonal cytopenia of undetermined significance (CCUS), low risk myelodysplastic…
- Conditions
- Clonal Cytopenia of Undetermined Significance, Essential Thrombocythemia, Myelodysplastic Syndrome, Myelofibrosis
- Trial name
- NCT06063486
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of Southern California
ITP - Immune Thrombocytopenia
Exploring the Efficacy, Safety of a Modified Starting Dosage of Avatrombopag in Immune Throbocytopenia (ITP) - a Pilot Study
This is a single-center, open label pilot trial where patients with primary ITP who require second line treatment will be offered avatrombopag at a reduced starting dose, adjusted thereafter according to the response and…
- Trial name
- Ava dosing (NCT07133659)
- Testing
- Avatrombopag 20 mg Oral Tablet
- Where
- Iraq
- Volunteers
- 25 people
- Sponsor
- Al-Mustansiriyah University
Immune Thrombocytopenia (ITP), ITP
A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)
The main objective is to assess the safety and tolerability of budoprutug in adults with ITP. Pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy will also be assessed.
- Conditions
- Immune Thrombocytopenia (ITP), ITP, Biologics, Monoclonal
- Trial name
- NCT07043946
- Testing
- Budoprutug
- Where
- 20 sites in Bulgaria, Greece and 3 more
- Volunteers
- 24 people
- Sponsor
- Climb Bio, Inc.
Immune Thrombocytopenia
Observatory of Immunological Thrombopenic Purpura in the Brest Region
Database of patients with ITP, diagnosed, treated and followed in the Brest University Hospital.
- Trial name
- OPTIMIST (NCT06556888)
- Where
- France
- Volunteers
- 500 people
- Sponsor
- University Hospital, Brest
Myelofibrosis (MF), Polycythemia Vera
MPNdpoint. Single-center, Retrospective, Prospective Study of the Outcome of Patients With Philadelphia-negative Chronic Myeloproliferative Neoplasms
Chronic myeloproliferative neoplasms (MPNs) are hematologic disorders of the myeloid lineage characterized by clonal proliferation of hematopoietic stem cells, high risk of thrombotic-hemorrhagic complications, and transformation…
- Conditions
- Myelofibrosis (MF), Polycythemia Vera, Essential Thrombocythaemia
- Trial name
- NCT07863466
- Where
- Italy
- Volunteers
- 1,190 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Purpura, Thrombocytopenic
Spanish-Portuguese Thrombotic Thrombocytopenic Purpura Registry
REPTT is an observational, prospective, multi-country, multicentre and non-interventional registry in which at least 300 patients with Thrombotic thrombocytopenic purpura (TTP) in Spain and Portugal will be evaluated.
- Trial name
- RE-PTT (NCT05914441)
- Testing
- Standard clinical practice
- Where
- 7 sites in Spain
- Volunteers
- 300 people
- Sponsor
- Fundación Española de Hematología y Hemoterapía
Refractory Immune Cytopenia
BCMA-CD19 CCAR T Cell Treatment of Refractory Immune Thrombocytopenia Associated with Autoimmune Diseases
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19 cCAR T cells in patients with refractory ITP associated with autoimmune disease.
- Trial name
- NCT06787989
- Testing
- BCMA-CD19 cCAR T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- iCell Gene Therapeutics
Ischemic Stroke
Transmission Electron Microscopy Images for Platelet Ultrastructural Criteria Before and After the Onset of an Antiplatelet Agent
The aim of the pilot study is to collect all the ultrastructural platelet characteristics by transmission electron microscopy before and after the onset of an antiplatelet treatment in patients hospitalized for an ischemic stroke…
- Trial name
- ELECTROSTROKE (NCT05004233)
- Testing
- Blood collection before antiplatelet treatment, Blood collection after antiplatelet treatment
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Primary Immune Thrombocytopenia (ITP)
A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids.
The purpose of this study is to assess the efficacy, safety and pharmacokinetics (PK) of ianalumab (VAY736) in addition to eltrombopag treatment; and to inform the dose of ianalumab in pediatric patients (5 to <18 years of age)…
- Trial name
- VAYHIT-P (NCT07660172)
- Testing
- Ianalumab, Eltrombopag
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals